EXECUTIVE INNOVATION LAB IN DIABETES AND PREDIABETES

PROGRAM AND PARTICIPANT BIOGRAPHIES
## AGENDA

### TUESDAY, JUNE 4

**Wingtip, 550 Montgomery St. 10th Floor, San Francisco, California**

- **6:30 PM**  Welcome Reception; Keynote by Harvard Business School historian Nancy Koehn, author of *Forged in Crisis*
- **7:30 PM**  West Coast Premiere of "A Touch of Sugar"

### WEDNESDAY, JUNE 5

**The Westin St. Francis, 335 Powell St, San Francisco, California**

- **6:45 AM**  Gather at Westin St. Francis lobby for Vitality Walk (optional)
- **7:30 AM**  Networking Breakfast, Mission Bay Ballroom (32nd floor)
- **8:30 AM**  Welcome and d19 Orientation
- **9:00 AM**  The dNetwork: Toward Movement-Level Strategic Action
- **10:00 AM**  Coffee Break
- **10:15 AM**  Levers for Changing the Landscape of Diabetes in America
- **11:30 AM**  Lunch and Tiny Habits
- **1:00 PM**  Levers for Change: Results and Exploration
- **3:15 PM**  Break
- **3:30 PM**  Levers for Change: Strategize and Refine
- **5:30 PM**  Evening Break
- **7:00 PM**  Cocktails & Dinner
  - "The diaTribe Foundation Award for Transformative Impact in Healthcare," Dr. Gary Puckrein, CEO, National Minority Quality Forum Inc.
- **8:00 PM**  Lightning Talks: Food as Medicine
  - James Gavin
  - Kelly Brownell
  - Akua Woolbright
  - Rita Nguyen
  - James Corbett
A MESSAGE FROM KELLY CLOSE

WELCOME TO D19

Welcome to d19: Executive Innovation Lab on Diabetes and Prediabetes. We are thrilled to have you as a part of the dSeries community.

Over the last three years, we have heard that the dSeries provides a unique opportunity for leaders from across the diabetes ecosystem to look at the type 2 epidemic in new ways. The dSeries gatherings are a space for learning, brainstorming, and honest discussion. We have explored tools, frameworks, and methodologies that help us reflect on the whole of the challenge before us more clearly, and act strategically together in ways that can meet the scale of the problem.

With d19, the dSeries evolves to produce a dNetwork of deeply visionary, strategic leadership and action. With your commitment, vision, passion, insight, and support, the thinking that happens at d19 will shape the story and future of the diabetes epidemic in America.

We want to look back in 5, 10, and 20 years on what we have accomplished and be able to say not just, “We had some good ideas,” but rather, “We dreamed big, we took risks, we took action, and we made a difference.”

At d19, we will be calling on all participants to step into a new kind of shared leadership that is collaborative, cross-sector, systemic, self-reflective, and visionary. We will ask you to help us identify priority areas for collective action, to co-design a strategic pathway forward, and to commit to participation that most aligns with the work you are already committed to doing in the world.

“We dreamed big, we took risks, we took action, and we made a difference.”

I’m looking forward to thinking and acting together to reach our shared vision of the future. I am honored that you have come to join us, as is our esteemed and dedicated board of directors, including Dennis Boyle, John Close, Jeff Halpern, Dr. Orville Kolterman, Dr. Alan Moses, and Marjorie Sennett. In closing, we would love to thank our steering committee members, design team members, participants, sponsors, our friends at Close Concerns and dQ&A, and the diabetes ecosystem (all of you who make us smarter every day). The diaTribe Foundation is forever grateful for your belief in our mission and assistance in our journey.

Onward!

Kelly L. Close
ABOUT THE DIATRIBE FOUNDATION

To fight the growing crisis of diabetes, The diaTribe Foundation was founded with the mission to improve the lives of people with diabetes and prediabetes and to advocate for action.

We’re committed to helping people with diabetes live happier, healthier, and more hopeful lives through our diaTribe Learn publication, which now reaches over two million people every year. We also aim to influence the national conversation, bringing the patient point of view to the FDA and to other policy makers, improving diabetes literacy in the media, and convening the world’s brightest minds to develop innovative solutions.

HOW DOES SOCIETY ADDRESS DIABETES?

There is no one single answer to the diabetes epidemic. It results from a diverse and complex set of circumstances. Solutions can only come from the joint effort and combined impact of many stakeholders.

We need to channel our collective intelligence to become smarter as a field. We need stronger and more directed collaboration among manufacturers, healthcare providers, researchers, government, and non-profits to improve patient outcomes. We need shared ownership of the diabetes epidemic to encourage aligned action.

WHERE DO WE COME IN?

The field of diabetes too often lacks unity, coordination, and clarity. The diaTribe Foundation wants to change that. Led by Kelly Close and a team of associates, we have the expertise to cover the diabetes landscape, a personal understanding of patient experiences, and an in-depth knowledge of diabetes pharmaceutical and biotechnology companies. We are a respected voice in regulatory and advocacy settings, and we have numerous partners in the diabetes online and advocacy communities. In short, we are well suited to catalyze a movement of change, progress, and hope.

THE PROBLEM

Over 30 million people in the US have diabetes. Over 8 million of them are undiagnosed. Another 86 million Americans have prediabetes.

14% OF ADULTS IN THE US HAS DIABETES
38% OF SENIORS IN THE US HAVE DIABETES
83% OF SENIORS HAVE DIABETES OR PREDIABETES

We need an integrated, cross-systems approach to reverse these trends.

ABOUT d19

d19 is a highly selective gathering of business, medical, scientific, policy, and education leaders from healthcare. The lab engages multi-stakeholder leaders to produce innovative and effective solutions in diabetes.

The diaTribe Foundation has access to a vast network of experts, particularly related to healthcare and science. Because we believe it is critical to involve thinkers from the entire diabetes ecosystem in meaningful conversation, we also seek to engage tech leaders, community health workers, government decision makers, educators, urban planners, major employers, and food industry and media representatives.

d19 is the fourth gathering of the smartest minds in and around diabetes.

BACKGROUND ON THE DSERIES AND PROGRESS UPDATES

The diaTribe Foundation has hosted three dSeries Executive Innovation Labs: d16 in Palo Alto, d17 in San Francisco, and d18 in Aspen. These gatherings were groundbreaking in several ways. First, they brought together a diverse group of participants from different sectors. Second, there were no panel discussions, talking heads, or pre-formulated outcomes. Participants engaged with one another and benefited from the blending of perspectives. In addition to forming long-lasting connections, the gatherings led to a number of comprehensive reports and high-impact documents. Those include the d16 and d17 Consensus of Ideas, each of which showcases 12 of the most investable, scalable, and meaningful ideas from their respective event. There’s also the Anthropology of Bright Spots, a document and web platform that sheds new light on the question of “What’s already working?” in type 2 diabetes and prediabetes.
A SPECIAL THANK YOU

TO OUR SPONSORS

The diaTribe Foundation would like to thank all our d19 sponsors: Sanofi, Merck, Abbott, AstraZeneca, Boehringer Ingelheim/Lilly, Novo Nordisk, and The Apple Pickers Foundation. We are proud to have them as partners in discovering new ideas and new opportunities at the d19 Executive Innovation Lab. We would like to thank these companies and foundations for their confidence in us and for their ongoing commitment to pioneering and patient-centric solutions for those with diabetes and prediabetes. These companies’ ongoing commitment to improving the lives of those living with diabetes is immensely valued, and our team is inspired by their engagement and passion for the cause.

Diabetes and cardiovascular disease affect millions of people worldwide, with many managing the complex challenges of both. Building on their portfolio evolution, heritage and expertise, Sanofi has a focused business unit dedicated to delivering innovative, value-based medicines and integrated solutions in these therapeutic areas. The company is committed to a collaborative approach that involves strategic alliances with professional and patient associations, research institutions, and leaders in healthcare and other industries, with the goal of advancing scientific knowledge, driving the convergence of science and technology, helping to improve outcomes, and inspiring an evolution in care.

Merck’s vision is to make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional, and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas—Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives.

Novo Nordisk, a global healthcare company, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey, we employ 6,000 people and operate in 160 countries. For more information, visit novonordisk.us, Facebook, Instagram, and Twitter.

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once- or twice yearly to prevent and/or chronically treat diseases holds potential to improve outcomes by improving effectiveness over time and by addressing real-world unmet needs around poor patient adherence and persistence rates that are high in the majority of chronic diseases. Intarcia is investigating multiple therapies, including combination therapies, for chronic diseases leveraging the convergence of novel medicines and the proprietary Medici Drug Delivery System.™ Intarcia is developing a strong pipeline in important therapeutic areas, including: diabetes (ITCA 650), obesity, autoimmune diseases, HIV, and other serious disorders.
Thank you

To our team

Our team at The diaTribe Foundation has been working tirelessly to make progress on the ideas that came out of d18. It has been exciting to watch this event grow and take shape into what you are attending today. And we could not have done it alone. In the spirit of d19, this entire gathering was the product of hard work and dedicated collaboration among many bright, talented individuals and organizations. I’d like to give thanks both to the members of our team who made d19 possible and to our “brain trust” partners who provided the guidance and support to make d19 a reality.

From The diaTribe Foundation, we thank our team members:

Our Board of Directors:
Dennis Boyle
John Close
Jeff Halpern
Dr. Orville Kolterman
Dr. Alan Moses
Marjorie Sennett
Jim Carroll
Chief Operating Officer
Caroline Pappajohn
Chief Strategy & Sustainability Officer
Mallory Erickson
Director of Strategic Partnerships and Organizational Development

Our Steering Committee members:
Kelly Brownell
James Corbett
Stefanie Cousins
Laura Martin Feinberg
Alan Moses

In addition, many thanks to our many friends and colleagues who work in the diabetes ecosystem, in the clinical, research, policy, advocacy, and business worlds more broadly, and to patients and care partners everywhere who make us smarter every day. The diaTribe Foundation is forever grateful for your belief in our mission and assistance in our dNetwork journey.

Yours truly,

Kelly L. Close

The facilitators

Chris Barnes

Chris Barnes is principal of Empathic Communications, a design consultancy that helps clients transform complexity into content that is easy for people to understand and use. Mr. Barnes has 25 years of experience providing creative services and consulting to global leaders in healthcare and the life sciences, including long-term clients in diabetes technology. His work spans a variety of organizational functions: from marketing, education, and scientific communications to internal systems and processes. In addition to corporate clients, Mr. Barnes has a specialized area of practice devoted to improving the delivery and experience of health care by making content and tools that better fit human needs. Over the past eight years, Mr. Barnes has worked with teams at Ariadne Labs (Safe Surgery, BetterBirth, Serious Illness, and Delivery Decisions initiatives), the World Health Organization, the CDC, Dana-Farber Cancer Institute, Johns Hopkins, and others to create simple cognitive aids and decision guides that shape care interactions. Mr. Barnes is co-organizer of Design for Healthcare, a Seattle-based group that brings together a diverse community of designers, care providers, patients, and others to explore how human-centered design can drive better patient and clinician experiences and improve outcomes.

@chris.barnes@emphaticinc.com

Denis Boyle

Dennis Boyle is a Partner and a founding team member of global design company IDEO, helping to lead its Design for Health portfolio. Design for Health works with clients in medical- and health-related industries to develop innovative products, software, services, and strategies. Mr. Boyle is also an adjunct professor at Stanford’s d.school and at the Design Division of the engineering school, where he has taught courses in product design, human factors design, design for sustainability, and creativity & innovation. He established and co-teaches “Design for Healthy Behaviors” at the d.school, which draws students from each of the university’s graduate schools. Students learn and use the design thinking process to help patient-volunteers with chronic conditions build healthy behaviors and thrive in their daily lives. Mr. Boyle holds a BS in Mechanical Engineering, with an emphasis on Industrial Design, from the University of Notre Dame and an MS in Product Design from Stanford.

@bjfogg | bjfogg

Dr. BJ Fogg is a behavior scientist at Stanford, where he directs research and innovation at the Behavior Design Lab. He also teaches his models and methods in graduate seminars. With industry, Dr. Fogg trains innovators to use his work so they can create solutions that influence behavior. His focus includes health, financial wellbeing, learning, productivity, and engagement. Dr. Fogg created a new method of habit formation called Tiny Habits. Using his online platform and email, he has personally coached over 40,000 people in creating habits. Fortune magazine named Dr. Fogg a “New Guru You Should Know” for his insights about mobile and social networks. Find out more at BJFogg.com and look forward to his upcoming book, Tiny Habits: The Small Changes that Change Everything, scheduled for publication in 2020.

@bjfogg | bjfogg
BROOKING GATEWOOD

Brooking Gatewood is a process designer, strategist, facilitator, and collaboration coach who brings a diverse toolkit to support leaders in executing change. Her work is rooted in the belief that we are wiser together. To that end, she focuses on fostering the creativity, collective intelligence, and collaborative leadership skills needed to affect systemic change on pressing public interest issues. Ms. Gatewood is a co-founder of the Emergence Collective and has collaborated with brilliant colleagues at Adaptive Edge, Groupaya, Ag Innovations, and beyond. She helped establish Earth Overshoot Day in her work with Global Footprint Network. The Stanford Social Innovation Review featured some of her more recent design work on patient-driven research. Brooking holds a bachelor’s in environmental studies from Dartmouth and a master’s in organizations and management theory from UC-Irvine.

R SCOTT SPANN

Scott Spann solves “impossible” issues/opportunities in business and in society. His work is inspired by his experience with business leaders—trying to do the right thing in complex, competitive situations; his work with social leaders in NGO’s and government—seeking to satisfy diverse stakeholders in ways that benefit the whole; his career as a Rolfer and trauma psychotherapist—witnessing people recover from the injuries that life and humanity too often deal us. Mr. Spann’s experiences range from consulting with Arthur Andersen to launching The Nature Conservancy’s Texas office; Managing EVP of RPC, a national consulting firm to leading the Rolf Institute; EVP for ARC, International, a global firm specializing in leadership development and cultural change to working for Stone Yamashita Partners, a global branding and strategy firm; from serving as CEO/COO for VC firms to working with former guerrilla and indigenous leaders in Guatemala. And he continues to learn by working with business and social leaders. Mr. Spann applied his successful strategic methodologies in businesses like Apple, HP and Humana; with social issues like climate change, affordable housing and social justice; and on complex projects for the U.S. Navy, the White House and many others.

@bn8

STEPHANIE WELDY

Stephanie Welsy is an expert at the intersection of employee health and Behavior Design. After spending a decade in the public sector, she manages operations and partnerships for Dr. BJ Fogg, a behavior scientist at Stanford University. Ms. Welsy supports his teaching and research in industry, collaborating with key partners, championing all aspects of project management, and optimizing Dr. Fogg’s ability to teach Behavior Design to help people be healthier and happier. Passionate about connecting people to resources that enhance their lives, Ms. Welsy previously led comprehensive wellbeing programs in higher education, non-profit, and government settings. She has a master’s degree in Education in Community Health from the University of Louisville and is a certified Wellcoach and Tiny Habits® coach.

KRIS WITTMANN

Kris Wittmann is a master strategic illustrator. Her extensive background in graphic arts, illustration, corporate training and higher education has given her the strong ability to visually capture tangible and abstract concepts that allow groups to “see” their challenges and create a clear path forward. In her strategic illustrations, Ms. Wittmann synthesizes information and provides a visual representation in real time. She creates large-format maps with concepts and data that are generously immersed with illustrations.

@wittmannstudios | wittmannstudios

d19 PARTICIPANTS

FARHANEH AHMADI

Eddi | Founder and CEO

Farhaneh Ahmadi is the Founder and CEO of Eddi, a creative digital health startup that engages users through a virtual buddy. Dr. Ahmadi did her MBA at Harvard Business School, where she focused on healthcare and founded Eddi. Prior to that, she was a management consultant at Oliver Wyman, London. Dr. Ahmadi also holds a PhD in Biochemistry from Cambridge University, UK.

@Farhaneh

BRADLEY ATKINSON

Merck | Team Leader, U.S. Medical Affairs—Merck Research Laboratories

Dr. Bradley Atkinson is a team leader of Medical Science Liaisons (MSLs) at Merck & Company Inc. In this role, he manages field-based MSLs who support clinical and scientific diabetes leaders and healthcare decision makers. As part of the Merck Diabetes US Medical Affairs Team, he assists in the development of Global Medical Affairs strategy to promote improved diabetes care and identify unmet treatment needs. He previously held pharmacy clinical, research, and leadership roles at The University of Texas MD Anderson Cancer Center in Houston, TX. He joined Merck in 2016, where his medical affairs experience includes virology and cardiovascular metabolic therapeutic areas. Brad earned his Doctor of Pharmacy degree from the University of Kansas School of Pharmacy and an MBA from Texas Woman’s University.

KRISTEN BINASO

Boehringer Ingelheim | Director of Patient Advocacy and Professional Relations—Primary Care

Kristen Binaso is the Director of Patient Advocacy and Professional Relations—Primary Care at Boehringer Ingelheim Pharmaceuticals, in Ridgefield, Connecticut. She is part of a team that is responsible for building and maintaining collaborative partnerships with key patient advocacy groups and professional medical associations with a focus on chronic disease management and primary care. Her background includes experience with the American Pharmacists Association, CVS/Pharmacy, Rite Aid and Target. Ms. Binaso holds a Bachelor of Science in Pharmacy from Rutgers, The State University of New Jersey, and is a Registered Pharmacist with a specialty focus on immunizations and geriatric care.
ADAM BROWN
Close Concerns | Head, Diabetes Technology and Connected Care; The diaTribe Foundation | Columnist and Senior Editor; Bright Spots & Landmines | Author

Adam Brown has worked at Close Concerns since 2010. He is the head of diabetes technology and digital health, bringing 16 years of personal experience with diabetes to his work. Mr. Brown has been highly involved in the expansion of technology coverage at Close Concerns, which includes glucose meters, CGM, insulin pumps, automated insulin delivery, diabetes software, mobile apps, and wearables. He also serves as a senior editor and frequent contributor at diaTribe.org, where his acclaimed column (Adam’s Corner) has brought diabetes tips to over one million people since 2013. His first book, Bright Spots & Landmines: The Diabetes Guide I Wish Someone Had Handed Me, was published in 2017 and has reached over 125,000 people through name-your-own-price downloads and purchases on Amazon. Mr. Brown graduated summa cum laude from the Wharton School of the University of Pennsylvania, pursuing concentrations in marketing and health care management and policy.

@asbrown1

TRACEY BROWN
American Diabetes Association (ADA) | Chief Executive Officer

Tracey D. Brown is Chief Executive Officer of the American Diabetes Association (ADA), the nation’s largest voluntary health organization. Ms. Brown herself has been thriving with type 2 diabetes for over 15 years. She is the first CEO in the organization’s almost 80-year history who has type 2 diabetes and is committed to stopping the diabetes epidemic. Ms. Brown joined the ADA in June 2018 after her tenure as Senior Vice President of Operations and Chief Experience Officer at Sam’s Club, a division of Walmart, Inc., where she was responsible for creating meaningful member experiences, directing member strategy, marketing and branding, go-to-market execution, data and analytics, and membership operations. Ms. Brown brings more than 25 years of experience in driving global business growth, leveraging data to connect consumers with brands, and creating omni-channel experiences to escalate customer loyalty. She has also served in leadership positions at American Express, Proctor & Gamble, and Exxon Mobil.

@Type2CEO | @type2ceo

KELLY BROWNELL
World Food Policy Center, Duke University | Director

Prior to joining the faculty at Duke, Dr. Kelly Brownell was at Yale University, where he was the James Rowland Angell Professor of Psychology, Professor of Epidemiology and Public Health, and Director of the Rudd Center for Food Policy and Obesity. Dr. Brownell has written 15 books and more than 350 scientific articles and chapters. He has served as President of several national organizations, including the Society of Behavioral Medicine, Association for the Advancement of Behavior Therapy, and the Division of Health Psychology of the American Psychological Association. Dr. Brownell has advised the White House, members of congress, governors, world health and nutrition organizations, and media leaders on issues of nutrition, obesity, and public policy. He was cited as a “moral entrepreneur” with special influence on public discourse in a history of the obesity field and was cited by Time magazine as a leading “warrior” in the area of nutrition and public policy.

★ dSeries Steering Committee

WILLIAM CEFALU
American Diabetes Association | Chief Scientific, Medical & Mission Officer

Dr. William T. Cefalu is Chief Scientific, Medical & Mission Officer at the American Diabetes Association, the global authority on diabetes. During his more than 30-year career as a physician, scientist, and health care leader, Dr. Cefalu has been an active leader with the Association—as a physician member and most recently serving as the Editor-in-Chief of Diabetes Care, the highest-ranked, peer-reviewed journal in diabetes, from 2012-2017. His clinical and basic science research has focused specifically on interventions to improve the metabolic state of individuals with insulin resistance and type 2 diabetes and in the cellular mechanisms for insulin resistance. Dr. Cefalu is widely published in journals, books, and book chapters, including more than 280 manuscripts and 25 book chapters. He has also served as the editor of five books on the management of diabetes. Cefalu earned his BS from Southeastern Louisiana University and his MD from LSU Health Science Center, New Orleans. He completed an Internal Medicine residency and served as Chief Resident at the University of California, Irvine, Veterans Affairs Long Beach Healthcare System.

@willcefalu

KELLY CLOSE
The diaTribe Foundation | Founder and Chair of the Board; diaTribe Learn | Editor-in-Chief; Close Concerns | President

Kelly Close founded The diaTribe Foundation, a nonprofit established in 2013 to improve the lives of people with diabetes and prediabetes and to advocate for action. She is Editor-in-Chief of diaTribe Learn, a free educational resource for people with diabetes. Ms. Close founded Close Concerns in 2002; its mission is to make everyone smarter about diabetes. At Close Concerns, Ms. Close and her team write about 3 million words a year on diabetes, prediabetes, obesity, and digital health for closerLook, a highly praised service covering the field. Ms. Close’s passion comes from her extensive professional work as well as from her personal experience, having had diabetes for over 30 years. Ms. Close’s previous work on Wall Street (investment banking at Goldman Sachs, equity research at Merrill Lynch) and at McKinsy & Company focused on life sciences. Kelly graduated from Amherst College and Harvard Business School.

@kellyclose | ★ dSeries Steering Committee

JAMES CORBETT
Initium Health | Principal

James Corbett is a seasoned healthcare executive and bioethicist bringing over a decade of chief level leadership experience from both the for-profit and the non-profit sectors of the industry. Mr. Corbett has served as a fellow at Harvard Medical School Department of Global Health and Social Medicine as well as at Harvard’s Safra Center for Ethics; he also recently completed a fellowship at the Nashville Healthcare Council. In addition, he was appointed to a 4-year term on the National Institutes of Health’s National Advisory Council for Nursing Research. He has worked in four health systems, where his focus has been on providing strategic and operational leadership for innovation, behavioral health, population health, research operations, global health, advocacy, and bioethics. Mr. Corbett has also lectured at Harvard Medical School, Harvard’s School of Public Health, and numerous other universities across the country. Mr. Corbett has been published in multiple books and journals. He earned his Bachelor of Science in International Relations from Syracuse University, his Juris Doctorate from St. John’s University, and his Master of Divinity from Duke University.

@JCETHICIST | ★ dSeries Steering Committee
Dr. Nichola Davis is the Senior Assistant Vice President of Chronic Disease and Prevention in the Office of Population Health and Hospitals. Previously, Dr. Davis was the Director of Ambulatory Medicine at New York City Health and Hospitals/North Central Bronx and Professor of Clinical Medicine in the Departments of Medicine, Division of General Internal Medicine, and Epidemiology and Population Health, Division of Behavioral and Nutritional Research at Albert Einstein College of Medicine. She received her B.S. from Sophie Davis School of Biomedical Education, her medical degree from New York University, School of Medicine in 1996 completed residency training in primary care internal medicine at Montefiore Medical Center in 1999 and Master of Science in Clinical Research Methods at Albert Einstein College of Medicine in 2003. Dr. Davis is board certified in Internal Medicine and Obesity Medicine. Dr. Davis’s clinical work focuses primarily on addressing obesity among low-income African-American and Latino communities particularly among those with diabetes. She strongly believes that helping people to lead healthier lifestyles is the foundation for improving health care outcomes, and is committed to finding ways to teach about and encourage healthier lifestyles through her work.

Casper de Clercq spends most of his time focused on technology approaches for payors and providers and commercializing medical devices, drug delivery systems, and digital health solutions. He is a partner at Norwest Venture Partners, where he focuses on mid-to-late-stage investments in consumer and digital health, healthcare IT, medical devices and diagnostics, and technology-enabled healthcare services. He currently serves on the boards of Omada Health, iRhythm Technologies, Crossover Health, and NextHealth Technologies. Mr. de Clercq was previously on the board of Basis (acquired by Intel), Intersect ENT, and Telcarea. Casper was also responsible for Norwest’s investment in Misfit Wearables (acquired by Fossil), Prior to Norwest, Casper was a Partner at US Venture Partners, where he invested in therapeutic companies from clinical development through commercialization. He is particularly interested in addressing chronic kidney disease, including leading a recent investment in Monogram. Over a six-year period, he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Mr. de Clercq was also a private investor and board member with Innomine, an orthopedic diagnostic company acquired by Kyphon in 2005. He has an AB in biochemistry from Dartmouth College and an MBA degree from Stanford University.
EMILY FITTS
The diaTribe Foundation | Senior Manager of Advocacy and Policy

Emily Fitts is the Senior Manager of Advocacy and Policy at The diaTribe Foundation and helps to lead regulatory- and policy-based initiatives to elevate the voices of people with diabetes and to advocate for action. Ms. Fitts has worked, in particular, on the Outcomes Beyond A1C movement, including helping to organize diaTribe’s 2017 consensus conference and publishing the subsequent report in Diabetes Care. Ms. Fitts joined The diaTribe Foundation as an Associate in 2017 after graduating cum laude from Amherst College with a degree in Psychology and a certificate in Culture, Health, and Science. She completed a senior honors thesis that investigated the social norms surrounding stress, sleep, and related disclosure and the influence of perfectionism on the misperceptions of such norms. Previously, Ms. Fitts was a Summer Associate for Close Concerns in 2016 and worked for The Union for International Cancer Control in Geneva, Switzerland, where she explored the business side of a public health nonprofit organization as the Business Development and External Relations intern.

FAITH FOREMAN-HAYS
Houston Health Department | Assistant Director

Dr. Faith Foreman-Hays is Assistant Director of the Houston Health Department and a seasoned public health practitioner and academician with more than 20 years of community and coalition building experience. In 2013, Dr. Foreman-Hays was tapped to lead the Cities Changing Diabetes (CCD) Global Public-Private Partnership aimed at reducing the burden of diabetes in urban populations. As the Assistant Director of the Houston Health Department, Dr. Foreman-Hays leads a team of nurses, health educators, wellness professionals, community health planners, and diabeticians. Dr. Foreman-Hays has a special passion for reducing health disparities among marginalized communities. Dr. Foreman-Hays earned her masters and doctorate in public health from the University of Texas School of Public Health, and her bachelor’s in sociology from Texas Southern University. She was also a National Institutes of Health Fellow. Dr. Foreman-Hays is licensed to practice nursing in Texas.

CHRISTOPHER GARDNER
Stanford University School of Medicine | Professor of Medicine

Dr. Christopher Gardner has a PhD in Nutrition Science and is a Professor of Medicine at Stanford’s School of Medicine. He has been researching the health effects of a plant-based diet and its components for 20 years, primarily with federal (NIH) funding. Recently his nutrition interests have expanded to two new areas. The first is to explore motivators other than health for making positive dietary changes, linking to ongoing social movements around animal welfare, climate change, social justice, and their relationships to food—health. The second is to focus on a food systems approach to dietary improvements that address the quality of food provided by schools, hospitals, worksites, food banks and other institutional food settings.

EMILY FITTS
The diaTribe Foundation | Senior Manager of Advocacy and Policy

Emily Fitts is the Senior Manager of Advocacy and Policy at The diaTribe Foundation and helps to lead regulatory- and policy-based initiatives to elevate the voices of people with diabetes and to advocate for action. Ms. Fitts has worked, in particular, on the Outcomes Beyond A1C movement, including helping to organize diaTribe’s 2017 consensus conference and publishing the subsequent report in Diabetes Care. Ms. Fitts joined The diaTribe Foundation as an Associate in 2017 after graduating cum laude from Amherst College with a degree in Psychology and a certificate in Culture, Health, and Science. She completed a senior honors thesis that investigated the social norms surrounding stress, sleep, and related disclosure and the influence of perfectionism on the misperceptions of such norms. Previously, Ms. Fitts was a Summer Associate for Close Concerns in 2016 and worked for The Union for International Cancer Control in Geneva, Switzerland, where she explored the business side of a public health nonprofit organization as the Business Development and External Relations intern.

TATIANYA GARRO
University of California, Irvine | Research Scientist

Dr. Tatiyana Garro is a Research Scientist at the University of California, Irvine, where she is studying the effects of dietary interventions on cognitive function in older adults. Her research interests include the role of diet, nutrition, and lifestyle in the prevention of age-related diseases such as Alzheimer's disease and cognitive decline. She completed her PhD in Biochemistry from Emory University and her postdoctoral training at the University of Colorado Health Sciences Center and at UCSD.

TIMOTHY GARVEY
University of Alabama at Birmingham | Chair, Department of Nutrition Sciences

Dr. Timothy Garvey is Professor of Medicine and Chair of the Department of Nutrition Sciences at the University of Alabama at Birmingham. Dr. Garvey has achieved international recognition for his research in insulin resistance, type 2 diabetes, and obesity. He has served as the principal investigator of an NIH-funded Program Project to study markers and mechanisms of diabetes vascular complications in collaboration with two national trial cohorts. Dr. Garvey also has a track record of community-based research and outreach in the context of two notable initiatives, Project Suga (a genetics study among Gullah-speaking African Americans) and MUSC/HBCU Partners in Wellness (a program in community health at six historically black colleges and universities in SC intended to engage minority students in the health professions). Dr. Garvey received his MD from St. Louis University, and he completed his residency training in Internal Medicine at Washington University. He also received his fellowship training at the University of Colorado Health Sciences Center and at UCSD.

JAMES R. GAVIN III
Healing Our Village, Inc. | Chief Medical Officer

Dr. James R. Gavin is a clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. He currently serves as Chief Medical Officer of Healing Our Village, Inc. Previously, he was president of the Morehouse School of Medicine in Atlanta. He served as senior scientific officer at the Howard Hughes Medical Institute and as director of the HHMI–National Institutes of Health Research Scholars Program. Dr. Gavin belongs to a number of organizations, including the National Academy of Medicine (formerly the IOM), the American Diabetes Association, the American Association of Clinical Endocrinologists, the American Society of Clinical Investigation, and the American Association of Physicians. He is a past president of the ADA and has been voted Clinician of the Year in Diabetes by the ADA multiple times. Dr. Gavin was named a “Living Legend in Diabetes” by the American Association of Diabetes Educators in 2009 and was named one of the “175 Emory History Makers” on the celebration of the University’s 175th Anniversary. In 2015, he received a Lifetime Achievement Award for Diabetes Research from ADA, and the Lifetime Meritorious Achievement Award from the NMA. Dr. Gavin has a MD from the Duke University School of Medicine and a PhD in Biochemistry from Emory University.

EDWARD GREISSING
Lynda and Stewart Resnick Center for Public Health | Executive Director

Edward Greissing is Executive Director of the Lynda and Stewart Resnick Center for Public Health at the Milken Institute. The Center, based in Washington, DC, builds upon the Institute’s past work in public health and accelerating cures. Mr. Greissing previously was senior vice president for corporate affairs and head of government affairs for Sanofi US. For more than three decades, Mr. Greissing led corporate public affairs and industry advocacy initiatives, first at Upjohn Company and later at Sanofi. At Sanofi, Mr. Greissing was responsible for a wide range of programs, including Chronic Disease Prevention and Wellness, Health Innovation, and Health and Economic Policy. His work has been recognized by others in life sciences, most recently receiving the American Cancer Society’s Donald H. Gerson Cancer Prevention and Public Policy Award. Before entering the industry in 1978, Mr. Greissing was on the staff of the U.S. Senate Intelligence Committee, where he contributed to a variety of investigations and reports. He earned an AB in History from College of the Holy Cross and an MA in Congressional Studies and Politics from The Catholic University of America.
YARON HADAD

Co-Founder and Chief Scientist
Nutrino

Dr. Yaron Hadad is a mathematical physicist whose expertise is in general relativity and nonlinear mathematics. Dr. Hadad is a co-founder and the Chief Scientist of Nutrino (acquired by Medtronic), where he leads the technological and scientific efforts of the company. Nutrino invented the FoodPrint - the digital signature of how different foods affect an individual's body. Nutrino applies the FoodPrint to help people living with diabetes understand how their food and lifestyle choices affect their glucose levels. Dr. Hadad spent over ten years developing and leading projects that leverage machine learning and AI in predictive analytics, recommendation, and optimization systems.

JEFF HALPERN

Senior Director of Marketing, Sensor Platform
Abbott Diabetes Care

Jeff Halpern is currently Senior Director of Marketing, Sensor Platform for Abbott Diabetes Care, where he is responsible for the global marketing, product management, and commercialization of Abbott’s sensor-based glucose monitoring systems. He brings a combination of strategic business skills, consumer marketing acumen, and experience to the diabetes device industry. Prior to joining Abbott, Mr. Halpern spent nine years at The Clorox Company in brand management for businesses, including Glad Food Storage and Clorox Cleaning Products. Since 1986, Mr. Halpern has held a variety of marketing and finance positions with major consulting, technology, and consumer packaged goods companies, including TheraSense, Wattage Monitor, Archway-Mother’s Cookie Companies, Swinglab LLC, Pacific Bell Mobile Services (aka AT&T Wireless), The Haagen-Dazs Company, and Bain & Company. Mr. Halpern received his AB from Brown University and his MBA from Stanford University Graduate School of Business. He has type 1 diabetes.

MANNY HERNANDEZ

SVP, Culture and Learning
Livongo Health

Manny Hernandez is a chronic-condition advocate who has had diabetes since 2002 and who lost his mother to Alzheimer’s in 2018. In 2008, Mr. Hernandez co-founded the Diabetes Hands Foundation (DHF), a global leader in diabetes social media and advocacy. In May 2015, he joined Livongo Health as VP, Member Experience and Strategic Product Partnerships. Since October 2017, he’s been Livongo’s SVP for Culture and Learning, responsible for creating an exceptional workplace and development experience for all Livongans.

ANDERS HVELPLUND

Executive Director, Clinical Development & Research
Novo Nordisk

Dr. Anders Hvelplund is Executive Director of Clinical Development and Research in Novo Nordisk North America. In his current role, he leads a team that has medical oversight of all Novo Nordisk clinical trials in North America for all therapeutic areas (Diabetes, Obesity, NASH, DKD, cardiovascular disease, bleeding disorders, and Growth Hormone disorders). His career at Novo Nordisk has spanned from medical affairs to product safety, with key activities in clinical development to support phase three programs, submissions, and regulatory interactions through approval and into lifecycle management. Dr. Hvelplund is a medical doctor by training, and before joining Novo-Nordisk he completed his PhD in cardiology using innovative registry solutions combined with clinical trial methodology to gain insights into inequality in patient care.

SAMI INKINEN

CEO & Founder
Virta Health

Sami Inkinen is the CEO & Founder of Virta Health in San Francisco. Virta is the first clinically proven treatment to safely and sustainably reverse type 2 diabetes without the risks, costs, or side effects of medications or surgery. Mr. Inkinen also invests in companies advancing human health and performance as an angel investor and as a Venture Partner at Obvious Ventures. Previously, Mr. Inkinen was a co-founder, COO, and President of Trulia, until its IPO and eventual sale for $3.6 billion. Mr. Inkinen, an avid athlete, is a triathlon world champion in his age group, and he recently rowed across the Pacific Ocean from California to Hawaii with his wife to raise awareness about healthy nutrition. Mr. Inkinen received his Master’s in Physics from the Helsinki University of Technology and an MBA from Stanford University.

CARL RASHAD JAEGE

Creative Director
Scott Street Films

The Big Idea of Carl Rashad Jaeger’s life is that moving images (film, TV, and video) can create fundamental change. As the VP of Marketing and PR of the Penfolds Group, Mr. Jaeger helped to build the Australian category of wine in North America through his work with global brands, such as Lindemans and Penfolds. At Robert Mondavi, Mr. Jaeger was selected to redesign all consumer-facing media (web, video, print, packaging) for this global brand and succeeded in reinvigorating sales in every region. These global brands in the wine industry awakened his creative soul, and he has helped businesses, charitable foundations, and television programs thrive. He earned his MBA from the Tuck Business School at Dartmouth College and his bachelor’s from Georgetown University. He and his team created the videos about d16 and d17.
Christina Jones is the Associate Director of Marketing, Key Markets Activation at Merck. In this role, she supports the Diabetes franchise in leveraging data and marketing insights to gain a deeper understanding of the regional/local market dynamics – specifically, the composition of the diabetes population within key markets, evaluating the emerging population health trends, and key cross-cultural considerations of care. Her career in marketing and sales includes leadership roles at GlaxoSmithKline, Oxford Health Plans, Wunderman Cato Johnson, and most recently Novo Nordisk. While at NNI, Ms. Jones supported multiple brand launches working across the organization in both Patient/HCP marketing roles with a focus on building Total Market plans. As the Multicultural lead for the Diabetes Portfolio, she was responsible for the development and execution of strategic and tactical plans that positively impacted diabetes care, treatment, and health outcomes across ethnic patient segments. Ms. Jones holds a B.A. in Psychology from West Chester University, an MS in Direct and Interactive Marketing from NYU, and is currently pursuing her MBA in Pharmaceutical & Healthcare Marketing at St. Joseph’s University.

Karen Jordan, and her husband Jeff, became involved with JDRF when their daughter Ali was diagnosed with T1D in 2008. Ms. Jordan serves on JDRF’s International Board of Directors. In addition, Ms. Jordan is President of JDRF’s Greater Bay Area Chapter Board and is a member of JDRF’s Research and Finance Committees. She is a founding board member of Carb DM, a non-profit providing education and support services to the T1D community, and is the organizer of the Bay Area Diabetes Consortium, comprised of 22 organizations serving the diabetes community in California’s greater Bay Area. Her previous non-profit work includes service on different boards including, among others, Starlight Children’s Foundation, Stanford GSB Alumni Association, and the Portola Valley School District. She was a member of the group who founded Summit Prep, a charter school profiled in Waiting for Superman. She also serves on the Stanford Healthcare Community Council. Ms. Jordan earned her M.B.A. from the Stanford University GSB and B.A. in Economics-Business from UCLA. She has also completed TPW’s year-long program on strategic philanthropy. She has worked as an investment banker and with the Mayor’s Office in Los Angeles.

Dr. Lee M. Kaplan is Director of the Obesity, Metabolism and Nutrition Institute and founding director of the Weight Center at the Massachusetts General Hospital, leading centers for obesity research, education, and clinical care. A gastroenterologist and molecular biologist by training, he is also an associate professor of medicine at Harvard Medical School. Dr. Kaplan is a world-renowned obesity researcher, clinician and educator and a strong advocate for better understanding, prevention, and treatment of the many forms of obesity. Dr. Kaplan earned an MD/PhD from Yeshiva University and completed his residency and fellowship at the Massachusetts General Hospital.
Dr. Orville Kolterman currently serves as the Chief Medical Officer for Whole Biome. His professional career has been dedicated to diabetes treatment and related clinical research. He has served as an academic investigator, serving as a Principal Investigator within the Diabetes Control and Complications Trial and the Epidemiology of Diabetes in control studies. He has also served as a management professional assisting with the growth and success of small, entrepreneurial biotechnology companies. Dr. Kolterman worked for over 20 years at Amylin Pharmaceuticals participating in the successful development of four novel therapeutic entities that received marketing approval in both the United States and Europe. Dr. Kolterman earned his MD from Stanford Medical School.

Sophie Koontz leads dQ&A’s research and production processes, product management and innovation, brand and product marketing, and recruitment and staffing. She focuses on process improvement and implementation. Previously, she managed the dQ&A Diabetes Connections – US Patient product, which synthesizes data and insights from over 5,000 people with diabetes every quarter. Prior to joining dQ&A, Sophie worked at a health technology non-profit and at the Department of Health and Human Services, where she analyzed data on the Affordable Care Act and the Children’s Health Insurance Program. Sophie has a BA in Human Biology from Stanford University.

After graduating Williams College in 2016, Brian joined Close Concerns, where he writes primarily about diabetes technology and digital health. For the past year, he has also worked part time at The diaTribe Foundation, helping to lead a project investigating the need for and feasibility of a healthcare provider-facing diabetes information resource. Prior to joining the 804 Haight family, Brian completed his senior thesis at Williams using optogenetics to investigate the effect of hypothalamic hunger circuit activation on sleep/wake architecture. Outside of the scientific realm, Brian is an avid drummer and music aficionado.

Dr. Jim McDermott is Vice President of US Medical Affairs, Metabolism, at AstraZeneca Pharmaceuticals. Dr. McDermott is responsible for leading medical strategy and Phase IV studies for the diabetes portfolio. He received his PhD in physiology from George Washington University in Washington, DC. While there, he served at the Naval Medical Research Institute as Principal Investigator responsible for identifying and testing novel treatments for central nervous system injuries related to diving accidents. At AstraZeneca, Dr. McDermott gained extensive experience as Clinical Lead for Phase II/III clinical trials assessing therapies for the treatment of stroke, Parkinson’s disease, and diabetes. Subsequently, he served as US Development Lead for the dapagliflozin clinical program. Dr. McDermott also headed the US integration of Amylin Pharmaceuticals with AstraZeneca. He holds a bachelor's degree in Biology from the University of San Diego, an MS in Biology from American University, and a PhD in Physiology from George Washington University.

Dr. Alan Moses is an independent consultant for the pharmaceutical and biotechnology sector. Trained in internal medicine and endocrinology, he spent the early part of his academic career at Harvard doing bench and clinical research and clinical care. Dr. Moses co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic. He joined Novo Nordisk in 2004. During his 14 years at Novo Nordisk, Dr. Moses served in multiple roles beginning as Associate Vice President of Medical Affairs for the US and rising to the position of Senior Vice President and Global Chief Medical Officer working in Copenhagen. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. He retired from Novo Nordisk in June 2018.

Angela Moskow is currently serving as a Senior Advisor at the Milken Institute Center for Public Health. Ms. Moskow has worked in healthcare for nearly three decades focused on building strong brands that meet patient and marketplace needs. Ms. Moskow was a principal in the launch of Sanofi’s blockbuster 24-hour insulin, Lantus, shepherding the brand for over 10 years. In 2011, Ms. Moskow started focusing on chronic disease prevention and wellness, specifically looking to prevent conditions like diabetes and obesity altogether. Most recently, Ms. Moskow led the Sanofi US Government Relations team. Ms. Moskow is a member of the Northwest Missouri State University Foundation Board, a member of the Alliance for a Healthier Generation Board of Directors, and she serves as a Women Unlimited, Inc. Mentor. Ms. Moskow has received awards from both The Women’s Venture Fund and Leading Women Entrepreneurs.
Dr. Elizabeth Murphy is Chief of the Endocrinology and Metabolism Division, Director of the Diabetes Center for High Risk Populations and Specialty Lead of the eReferral Program at Zuckerberg San Francisco General Hospital. She is also a Professor of Clinical Medicine at the University of California, San Francisco. As Chief of the Endocrinology and Metabolism Division at ZSFGH, Dr. Murphy focuses on improving access and quality of endocrinology and diabetes care for low-income, diverse populations in San Francisco. Her team has developed novel services and tools for insulin initiation in English, Spanish and Chinese including low literacy insulin teaching aids and patient videos addressing insulin fears in addition to medication management algorithms for primary care, and targeted outreach to San Francisco County Jail patients. Their current focus is spearheading a diabetes prevention program across the San Francisco Safety Net. Dr. Murphy received her BA in Chemistry from Wellesley College, a DPhil in Biochemistry from Oxford University as a Rhodes Scholar, and an MD from Harvard Medical School in the Harvard-MIT affiliated Health Sciences and Technology program.

Jennifer Nadelson has more than 20 years of experience in mission-driven, fast-paced organizations, where she has served in leadership roles in the education and healthcare sectors. She was the Executive Director of Primary Care Progress (PCP), a national social enterprise for primary care clinicians. She was also the Director of Operations at Ariadne Labs, Atul Gawande’s research think tank, where she shepherded the organization through a challenging joint venture structure and a quadrupling in size and capacity. She assumed these roles after almost nine years in various senior levels of hospital administration at Brigham and Women’s Hospital in Boston. Currently she is providing management consulting services to healthcare and non-healthcare related organizations. Her work is focused on helping fast-growing organizations establish the structures and systems needed to secure their next steps. Ms. Nadelson holds an M.B.A. from Northeastern University, a Master’s in Urban Planning from Columbia University, and a B.A. in History from Barnard College.

Dr. K.M. Venkat Narayan is a member of the US National Academy of Medicine (NAM) and is currently the Ruth and O.C. Hubert Chair of Global Health; Director, Emory Global Diabetes Research Center; Director, Georgia Center for Diabetes Translation Research, and Professor of Medicine & Epidemiology at Emory University in Atlanta. Dr. Narayan is noted for substantial, multidisciplinary work in diabetes public health, with nearly 450 publications, including several high-impact studies. Prior to his time at Emory, Dr. Narayan spent 10 years at the U.S. Centers for Disease Control and Prevention, leading efforts in his role as chief of the Diabetes Epidemiology and Statistics Branch. He was also an intramural researcher at the National Institute of Diabetes and Digestive and Kidney Diseases. His research has focused on the epidemiology of type 2 diabetes and on large national and international observational and intervention studies to prevent and control the disease.

Dr. Rita Nguyen is a Bay Area native whose interests are founded on a desire to unite the humanitarian promise of medicine with the pursuit of social justice. Her public service work has been primarily community-based and focused on addressing inequities faced by underserved communities. In terms of addressing healthcare access, Dr. Nguyen helped found Pacific Free Clinic, a Stanford-affiliated, student-run free clinic on the east side of San Jose. As Medical Director of Healthy Food Initiatives at ZSFG, she spearheaded several projects that emphasize the importance of food and health including creating Food Pharmacies where patients can fill prescriptions for healthy diets written by their providers and a transitional meal program that partners with Project Open Hand to deliver medically tailored meals to patients discharged from ZSF with heart failure. As an Assistant Health Officer and Chronic Disease Physician Specialist for the San Francisco Department of Public Health, she helps lead and support chronic disease and cancer prevention efforts for the City and County of San Francisco. Dr. Nguyen holds a BA in Human Biology from Stanford University and an MD from Johns Hopkins University School of Medicine.

Dr. Michael O’Donnell is CEO of the Art and Science of Health Promotion Institute. He is also founder and editor-in-chief emeritus of the American Journal of Health Promotion, founder and program chair of the Art and Science of Health Promotion Conference, and founder and chairwoman of Health Promotion Advocates. He has worked directly with more than 150 employers, health care organizations, government agencies, foundations, insurance companies and health promotion providers to develop and refine health promotion programs, products, policies, and legislation and has served in leadership roles in four major health systems, including the Cleveland Clinic. He has authored more than 200 articles, book chapters and columns and 6 books and workbooks, including Health Promotion in the Workplace, which has been in continuous publication since 1984 and translated into four languages. Dr. O’Donnell conceived and authored legislation that was incorporated into the Affordable Care Act, including provisions that resulted in production of the annual National Prevention Strategy. He earned a PhD in Health Behavior from University of Michigan, an MBA in General Management and an MPH in Hospital Management, both from University of California, Berkeley, and an AB in psychology from Oberlin College.
Robert Oringer has over 35 years of experience as an entrepreneur, investor, and board leader in healthcare, primarily in diabetes medical devices and services. Thanks to his extensive experience, Mr. Oringer brings a unique perspective in guiding development of novel products and approaches to the self-management of diabetes and its complications. Mr. Oringer is currently Chairman of Locemia Solutions, a Montreal-based specialty pharmaceutical company focused on innovating the delivery of drugs through intranasal powder formulations. Locemia’s initial work was directed at making severe hypoglycemia rescue simple through the development of an innovative needle-free nasal glucagon powder that is easy to teach, easy to carry, and easy to use. Locemia’s nasal glucagon powder assets were sold to Eli Lilly in October 2015. Mr. Oringer is an active early-stage diabetes investor in numerous companies, including Agamatek, Bigfoot Biomedical, Bioling, Capillary Biomedical, Diasome, dlife, Glyens, HelpAround, and WellDoc. Mr. Oringer’s focus on diabetes stems from the experience of raising his two sons who have type 1 diabetes.

Casey Palmer, MS, RN is a Research Analyst with Dr. Laura Schmidt’s team at the Institute of Health Policy Studies at UCSF. Her work focuses on research that aims to understand the contributing influences on and solutions to overconsumption of unhealthy commodities and the resulting obesity and cardio-metabolic diseases. She also has a background in global preterm birth research as well as several clinical years as a Labor and Delivery RN.

Dr. Gary A. Puckrein is the President and CEO of the National Minority Quality Forum Inc. (NMQF), a nonprofit organization that he founded in 1998. Under his leadership NMQF launched the Zip code Analysis Project (ZCAP). ZCAP is a comprehensive database that links vital statistics, demographic, environmental, claims, prescription drug, clinical laboratory values, health care access points (for example, hospitals or physicians’ offices) and other data elements into one centralized data warehouse, organized around Zip codes. ZCAP enabled the NMQF to develop the Health Assessment Tool (HAT) that measures and forecasts health status in small geographic areas, evaluates the impact of specific interventions, monitors changes in health outcomes, and undertakes risk assessments (health care utilization and its financial implications). NMQF uses HAT to provide a common set of indicators – geographic and health status referents – to stratify communities by health status. Dr. Puckrein possesses a unique business and academic background. He graduated Phi Beta Kappa from Brown University where he received his doctorate (1978) and masters degree (1974). Dr. Puckrein has received many awards and honors, including being named a visiting scholar and fellow at the Smithsonian’s National Museum of American History and a visiting fellow at Princeton University.
Dr. Laura Schmidt works to understand how changing lifestyles are contributing to globally rising rates of chronic disease. She bridges the worlds of biomedical research and population health in exploring the growing pressures of globalizing economies, rising inequality, and the marketing of products that are undermining our health. She is the lead investigator on SugarScience, which educates the public about the latest science on sugar. Dr. Schmidt also works directly with decision makers to promote scientifically substantiated social policy reforms.

@lauraschmidtmd

Eloise Scavella is Chief Operating and Strategy Officer of the American Diabetes Association (ADA), the nation’s largest voluntary health organization. Ms. Scavella is responsible for managing the operations of the ADA to drive sustainable growth. She is also responsible for leading the development, execution, and monitoring of the ADA’s strategic plan internally and externally. Prior to joining the ADA, Ms. Scavella was the Vice President of Global Learning and Development at Walmart. She was tasked with finding, developing, and moving critical talent in the organization, empowering talent to individually author their careers, driving experiential learning to prepare leaders for future business models, and leveraging data-driven insights to identify, select, and position leaders in the business. Prior to Walmart, she worked at Caesars Entertainment in Las Vegas, where she served in various capacities, including Associate General Manager and Corporate Vice President of Employment and Training.

@adachiefops

Dr. Urmimala Sarkar is Associate Professor of Medicine at UCSF in the Division of General Internal Medicine, Associate Director of the UCSF Center for Vulnerable Populations. She is also a primary care physician at Zuckerberg San Francisco General Hospital’s Richard H. Fine People’s Clinic. Dr. Sarkar’s research focuses on innovating for health equity. Her research employs new tools like digital/mobile health and social media to improve the safety and quality of outpatient care. She has expertise in medical errors and patient safety, diabetes, and cancer prevention and survivorship. This research incorporates collaboration with a range of experts, including those involved in design thinking/usability testing, human factors engineering, data science, health services research, and implementation science.

@iUrmimalaSarkar

Cherise Shockley was diagnosed with LADA (Latent Autoimmune Diabetes in adults) in June 2004. She is the founder of Diabetes Social Media Advocacy (#dsma), creator of the Blue Fridays initiative and WOCDiabetes (Women of Color living with Diabetes). Cherise is a subject matter expert in diabetes social media, online communities, and peer support. She is a wife, mother, and veteran. Cherise leads organic social media for Roche Diabetes Care US.

@cheriseshockley

Marjorie Sennett is CEO of The diaTribe Foundation — the organization that launched Good Measures and diaTribe — a $700 million portfolio of investments in biopharmaceutical, medical device, and diagnostic companies, including several in the diabetes industry. She understands the complexities of the diabetes ecosystem, the operational challenges of building entrepreneurial companies, and the return expectations of institutional investors. Over the past four years, she served as a member of the Board of Directors and Audit Committee of QuinStreet, a publicly-traded performance marketing technology company. Since 2017, she has served on the Board of Directors of The diaTribe Foundation and is Chair of its Audit Committee. Ms. Sennett earned an MBA from the Stanford Graduate School of Business and a BA, magna cum laude, in Biology and English from Vanderbilt University.

@marjoriesennett

Stefany Shaheen has dedicated herself to making life better for people living with diabetes. Her book, Elle & Coach: Diabetes, The Fight for My Daughter’s Life, & The Dog Who Changed Everything, is the New York Times bestseller about the challenges and beauty of parenting a child with type 1 diabetes. Ms. Shaheen launched a company to help those manage chronic conditions. She is on the Board of Trustees at Joslin Diabetes Center, served as the National Chair for the Juvenile Diabetes Research Foundation Children’s Congress, and currently serves on the Foundation’s Advocacy Committee. She is a spokesperson for her mother, Jeane Shaheen, U.S. Senator and former New Hampshire Governor, and she served on the City Council for the City of Portsmouth, New Hampshire. A graduate of MIT’s Sloan School of Management and Harvard’s Kennedy School of Government, Ms. Shaheen was also a student delegate to the International Academy of Achievement. She graduated magna cum laude from Fairfield University while competing as a Division I scholarship athlete.

@stefanyshaheen

ROCHE | Social Media Marketing Specialist, Diabetes Care

CURRICULUM VITAE

Cherise Shockley was diagnosed with LADA (Latent Autoimmune Diabetes in adults) in June 2004. She is the founder of Diabetes Social Media Advocacy (#dsma), creator of the Blue Fridays initiative and WOCDiabetes (Women of Color living with Diabetes). Cherise is a subject matter expert in diabetes social media, online communities, and peer support. She is a wife, mother, and veteran. Cherise leads organic social media for Roche Diabetes Care US.

@cheriseshockley

Stefany Shaheen has dedicated herself to making life better for people living with diabetes. Her book, Elle & Coach: Diabetes, The Fight for My Daughter’s Life, & The Dog Who Changed Everything, is the New York Times bestseller about the challenges and beauty of parenting a child with type 1 diabetes. Ms. Shaheen launched a company to help those manage chronic conditions. She is on the Board of Trustees at Joslin Diabetes Center, served as the National Chair for the Juvenile Diabetes Research Foundation Children’s Congress, and currently serves on the Foundation’s Advocacy Committee. She is a spokesperson for her mother, Jeane Shaheen, U.S. Senator and former New Hampshire Governor, and she served on the City Council for the City of Portsmouth, New Hampshire. A graduate of MIT’s Sloan School of Management and Harvard’s Kennedy School of Government, Ms. Shaheen was also a student delegate to the International Academy of Achievement. She graduated magna cum laude from Fairfield University while competing as a Division I scholarship athlete.

@stefanyshaheen
ANDRA STEVENSON
Merck & Company Inc., Director, US Medical Affairs for General Medicine

Dr. Andra Stevenson is Director, US Medical Affairs for General Medicine, at Merck. He serves as the scientific strategic lead to the field medical teams supporting cardio-metabolic diseases, respiratory, neuroscience, and women’s health. Prior to joining Merck, Dr. Stevenson was UNCF-Merck Postdoctoral Fellow at the University of Virginia School of Medicine and Assistant Professor at The University of Virginia School of Medicine, researching broad areas within vascular diseases and muscle physiology. During his 13-year tenure at Merck, he has continued to gain extensive expertise and experience in Diabetes, Cardiovascular Diseases (i.e., atherosclerosis, heart failure, hypertension, pulmonary hypertension, and thrombosis) as well as in cross-functional areas including respiratory, urology, and neuroscience. Dr. Stevenson has led efforts from new target identification through late stage clinical development, including roles within Medical Affairs, Global Scientific Affairs, and Global Clinical Development. Dr. Stevenson received his bachelor’s degree in Biology and his PhD in Pharmacology from The University of Vermont College of Medicine.

LORRAINE STIEHL
The diaTribe Foundation, National Diabetes Advocate

Last year, Lorraine Stiehl was appointed by the US Secretary of Health and Human Services to the NIH’s NIDDK Advisory Council. Over the last 30 years, Ms. Stiehl has provided management, marketing, fundraising, and strategic planning guidance to dozens of non-profits, government entities, and academic institutions and currently consults for UCSF on diabetes clinical trial recruitment. Ms. Stiehl helped to create the Florida Diabetes Prevention Program, working with the CDC and Florida Department of Health, and serves as a trained DPP Lifestyle Coach. Ms. Stiehl was employed by the UCSF Diabetes Center for 13 years, and she has worked with JDRF for over 30 years, receiving both the “National Staff Member of the Year” award (1992) and the “National Volunteer of the Year” award (2010). Ms. Stiehl recently co-published a book, What to Do When Your Partner has Diabetes: A Survival Guide.
SANJAY TREHAN  
**Sanofi | Associate Director of Global Business Development**

Sanjay Trehan is an Associate Director of Global Business Development at Sanofi, where he leads strategic collaborations, acquisitions, and partnering efforts across the Sanofi Genzyme portfolio. Mr. Trehan has been responsible for licensing deals with an aggregate value of over $1 billion and these activities have resulted in successful co-development programs, collaborative commercialization, and the research and development of products from preclinical research to late stage development. Prior to Sanofi, Mr. Trehan held multiple roles at Genentech, spanning both R&D and commercial, with a focus on diabetes and cardiovascular diseases. He started his career at Close Concerns, overseeing the pharmaceutical coverage of the Closer Look publication. Mr. Trehan holds BS in Computational Biology from Brown University and an MBA from the MIT Sloan School of Management.

@strehan  |  dSeries Steering Committee

VIRGINIA VALENTINE  
**Advanced Practice Nurse-Clinical Nurse Specialist**

Virginia Valentine is a Diabetes Specialist with Clinica La Esperanza in Albuquerque, New Mexico. She is also a faculty clinician with Endo Echo with University of New Mexico. Project ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of medical education and care management that empowers clinicians across New Mexico to provide better care to more people, right where they live. Ms. Valentine received her master’s in nursing from the University of Oklahoma College of Nursing. She is board-certified in Advanced Diabetes Management and is a Certified Diabetes Educator. In 2006, the American Association of Diabetes Educators recognized her with its Distinguished Service Award and awarded her Fellow status in 2010. Ms. Valentine has been awarded the 2019 Outstanding Educator in Diabetes by the American Diabetes Association. She has been living well with type 2 diabetes for over 35 years.

★ dSeries Steering Committee

TERRY VANCE  
**Close Concerns | Advisor**

Terry Vance is an advisor to Close Concerns. Previously, he was Chief Business Officer of BioMotiv LLC. Mr. Vance was the Managing Member of EGS Healthcare Capital Partners, a late-stage venture capital fund that he co-founded in 2000. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotech companies. Mr. Vance holds an AB degree from Princeton University and an MBA degree from Stanford University.

DENEE WADHWA  
**UnitedHealth Group | Executive Vice President Research and Development**

Dr. Deneen Voja is Executive Vice President, Research & Development at UnitedHealth Group. She is Chief Medical Officer of the Global Research and Development group, which focuses on accelerating enterprise innovation solutions to improve health care quality, reduce care costs, more effectively engage consumers in their health, and help modernize the health system. She consults with states, universities, foundations, insurance and disease management companies, and other organizations interested in improving the health outcomes of their constituency with a particular emphasis on obesity and diabetes. After training in Pediatrics at the Children’s Hospital of Philadelphia, Dr. Voja served as Senior Vice President/Chief Medical Officer of Health Partners and subsequently, the Frankford Health Care System. Dr. Voja earned her BA from the University of Pittsburgh and her MD from Temple University School of Medicine.

@DrVoja  |  ddvojta

SANDEEP WADHWA  
**Solera Health | Chief Health Officer & Senior Vice President, Market Innovation**

Dr. Sandeep Wadhwa is a leader in building population health programs for vulnerable populations. He serves as the chief health officer for Solera Health where he is focused on scaling the Diabetes Prevention Program by building a national network of community DPP providers, contracting with health plans and then preference matching their members to convenient DPP classes. Previously, Dr. Wadhwa served as the State Medicaid Director for Colorado from 2008 to 2010. He held leadership population health positions at 3M, McKesson and Noridian. Dr. Wadhwa serves on the board of directors of Reinvestment Fund, a $1 billion non-profit, financial institute devoted to revitalizing low-income neighborhoods. He continues sees patients at the Seniors Clinic at the University of Colorado Hospital. He earned his BA at Wesleyan, MD at Cornell and MBA Wharton and is dual board-certified in internal medicine and geriatrics.

@DrVojta  |  ddvojta

KRISTEN WILLIAMS  
**AstraZeneca | Director, US Alliances & Advocacy**

Kristen Williams joined AstraZeneca in May 1998 as a Marketing Communications manager and brought with her nearly 10 years of experience in public affairs. She has held various public relations, strategic planning, and fund development positions with the United Way of Delaware, The Office of the Governor, The U.S. House of Representatives, Office of Michael N. Castle, The College/UNCF, and the YWCA. Currently, Ms. Williams is the Director of Alliances & Advocacy for AstraZeneca’s US business. She has been responsible for leading efforts across the US in alliance building with patient, civic, and professional organizations important to AstraZeneca’s patient health objectives across therapeutic areas. Ms. Williams received a bachelor’s in political science from Spelman College and an MPA from the University of Delaware’s College of Urban Affairs and Public Policy.
Richard Wood
dQ&A | CEO

Richard Wood is CEO of dQ&A, the diabetes market research company that he founded with Kelly and John Close in 2009. dQ&A focuses on helping companies understand the diabetes patient and healthcare provider landscapes through syndicated and custom research programs. Mr. Wood was previously Vice President of Consumer Insights at Nielsen, where he managed all consumer market research programs for the mobile telecoms industry in the USA, Europe, and Asia. He has extensive experience from a 20-year career in consumer and industry research, software, and publishing; and he holds an MBA from INSEAD.

Akua Woolbright
Whole Cities Foundation

With a Ph.D. in Nutritional Science and an MA in Sociology, Dr. Woolbright has been a strong ambassador for community health elevation for many years. As the Wellness Educator at Whole Foods Headquarters, Dr. Woolbright develops healthy eating and outreach programs, conducts educational trainings, and coordinates regional and local healthy eating specialists. Dr. Woolbright has been hands-on and worn many hats in her nutrition career, working as both an HIV nutritionist and research associate at Howard University Hospital, as a cooking instructor for The Cancer Project, and as a Public Health Nutritionist for Washington D.C.’s Department of Public Health. Dr. Woolbright is a Ph.D. graduate of Howard University and received her Bachelor’s degree at Southern Methodist University.

Deana Zabaldo
Advisor | Capacity for Success

Deana Zabaldo has been a catalyst for change at diverse organizations in both the U.S. and Nepal. She currently coaches leaders and entrepreneurs toward greater success and also spends time each year in the Himalayas, as an award-winning professional guide and as founder of the grant-making fund Changing Lives Nepal. Ms. Zabaldo’s prior experience includes expanding education and training in a manufacturing facility for Lucent Technologies, launching cross-cultural programs as a Director for Intrax Cultural Exchange, building classrooms as a U.S. Peace Corps Volunteer, and launching a grassroots non-profit to address poverty in Nepal. She holds a master’s in behavioral psychology from the University of Florida, has practiced meditation and yoga for over 20 years, and has an abiding dedication to make a positive impact in people’s lives.

Jim Carroll
The diaTribe Foundation | Chief Operating Officer

Jim Carroll comes to The diaTribe Foundation after seven years as the Vice President of Finance and Administration at Common Sense Media and six years as the Managing Director of Equality California, where he led the team to successfully pass more than 70 pieces of legislation to achieve legal equality for LGBT Californians. He also worked at an environmental health organization called The Breast Cancer Fund and at the national office of Parents, Families and Friends of Lesbians and Gays. Mr. Carroll graduated from the University of Florida and lives with his husband, Scott, and their two yellow Labrador Retrievers in San Francisco.

Mallory Erickson
The diaTribe Foundation | Senior Director of Strategic Partnerships & Organizational Development

Mallory Erickson joined The diaTribe Foundation in 2017 as its first Managing Director. Ms. Erickson brings nearly 12 years of non-profit leadership experience, with a focus on strategic planning, capacity building, program development, and management. She graduated from the University of Michigan in 2007 pursuing concentrations in Sociology and Political Science, with a focus on education and social change. She received her Master’s in Education from Lesley University through a teaching fellowship with Citizen Schools, where she became Campus Director. Following her role at Citizen Schools, Ms. Erickson became a non-profit consultant and supported organizations to train their first-year AmeriCorps members. For the last five years, Ms. Erickson has been the Managing Director and Executive Director for Global Student Embassy (GSE). At GSE, she transformed a startup non-profit into a thriving organization with environmental youth leadership programs in three countries, sustainable gardens in 20 Bay Area high schools, and with student groups on 18 university campuses throughout the United States. Ms. Erickson is passionate about traveling, exercise, recycling, reading, and art. She spends her free time hiking around the Bay Area or exploring a new country.
DIVYA GOPISETTY
The diaTribe Foundation | Senior Associate

Divya Gopisetty started as a summer intern at Close Concerns in 2017 and joined The diaTribe Foundation as a full-time associate in 2018 after graduating from Stanford University with a B.A. in Human Biology. Ms. Gopisetty’s younger sister was diagnosed with type 1 diabetes 11 years ago. Her resilience has inspired Ms. Gopisetty to work in diabetes for the last four years in a variety of roles, including clinical research, patient advocacy, and community engagement. During her senior year, she co-directed a novel design challenge, Disrupt Diabetes, which created a new framework for patient-driven innovation. At diaTribe, she is co-leading diaTribe’s d19, an Executive Innovation Lab that seeks to tackle the type 2 diabetes epidemic from a systems approach. Ms. Gopisetty is also passionate about using diaTribe’s education and advocacy efforts to highlight diverse patient voices. In the future, she hopes to have a diabetes clinical practice while also working to prevent chronic disease in vulnerable populations.

jeemin.kwon@diatribe.org

JEEMIN Kwon
The diaTribe Foundation | Senior Associate

Jeemin Kwon joined The diaTribe Foundation in 2017 after graduating cum laude from Yale University with a BS in Molecular, Cellular, & Developmental Biology. As an undergraduate, she focused on neurobiology, culminating in a senior project researching the effects of inhibiting a brain-specific protein in Alzheimer’s disease. She also pursued other academic interests related to psychology and public health. At diaTribe, Ms. Kwon is the Managing Editor of diaTribe Learn, the online educational platform for people with diabetes and prediabetes. She has helped to grow the subscriber list to over 180,000 and the yearly web traffic to 2 million people and is focused on bringing new people to diaTribe by producing articles that help people lead healthier and happier lives. Ms. Kwon also runs the diaTribe Twitter account @diaTribeNews. In addition to diabetes and other matters of health, Ms. Kwon is passionate about boba, exploring cities on foot, and animated films. This summer, she will begin medical school at The Perelman School of Medicine at the University of Pennsylvania as part of the Twenty-First Century Scholars Program.

jeemin.kwon@diatribe.org

ALIJAH MARQUEZ
The diaTribe Foundation | Manager of Strategic Partnerships and Development

Alijah Marquez joined The diaTribe Foundation in 2018 as its first Development Coordinator. Ms. Marquez completed her Bachelor Degree in Collaborative Health and Human Services at California State University, Monterey Bay, in 2014 and her Master in Public Health degree at San Jose State University in 2017—both with an emphasis on community health. Ms. Marquez brings over five years of non-profit involvement, with a focus on health education, program development and implementation, community outreach, and organizational development. Ms. Marquez has served as a long-standing volunteer and intern for numerous health-related nonprofits, which include The Compassionate Friends bereavement support organization, Planned Parenthood Mar Monte, Community Health Resource Center, and the Brisbane Lions Club. Ms. Marquez is passionate about health and wellness, sustainable and recycled fashion, animals, vegetarian food, and coastal hikes.

alieh.marquez@diatribe.org

CAROLINE PAPPAJOHN
The diaTribe Foundation | Chief Strategy & Sustainability Officer

Caroline Pappajohn joined The diaTribe Foundation in 2018, where she brings her passion and expertise in strategy, product management, and development to help improve the lives of people with diabetes. Most recently, Ms. Pappajohn was director of strategy and innovation for Providence Health & Services in Portland, Oregon, where she worked with service line executives to decide how to create the greatest value. Prior to healthcare, Ms. Pappajohn spent a dozen years in nonprofit leadership, including a decade at New Door Ventures in San Francisco, where she helped grow fundraising revenues 450% in three years and started a new social purpose cafe to help at-risk youth transition to a healthy adulthood. She also spent a decade in high tech in the Bay Area, launching and marketing new products for a global telecom software company and an Internet start-up for women’s sports gear that she co-founded. Ms. Pappajohn began her career as a policy advisor to US Senator Arlen Specter in Washington, D.C., where she learned to tackle thorny issues with a mixture of determination, impatience, compromise, and creativity. Ms. Pappajohn has a BA in Political Science and an MBA from Stanford University.

caroline.pappajohn@diatribe.org

EMMA RYAN
The diaTribe Foundation | Senior Associate

Emma Ryan joined The diaTribe Foundation in 2017 after graduating cum laude from Amherst College with a degree in Law, Jurisprudence, and Social Thought. At diaTribe, she helps lead the dSeries Executive Innovation Labs, which foster systemic change to address the type 2 diabetes epidemic and improve the health of our nation. Ms. Ryan also writes for diaTribe.org with a particular interest in the cost of care, insurance coverage, and health policy. She focused on the intersection of science and community during her time at Amherst, writing a thesis on the impact of functional neuroimaging on criminal responsibility and helping launch an initiative to improve the experience of underrepresented minority students studying science and math. Ms. Ryan was also a captain of the women’s rowing team, a volunteer ESL tutor, and a staff writer for a humor publication. She will begin at the University of Washington School of Medicine this summer.

emma.ryan@diatribe.org

JIMMY MCDERMOTT
The diaTribe Foundation | Senior Associate

Jimmy McDermott joined the diaTribe Foundation in 2018 after graduating cum laude from Georgetown University’s School of Foreign Service. He majored in science, technology, and international affairs, with a focus on security and global health. As an undergraduate, Mr. McDermott worked for a Washington, DC-based policy research organization to assist in US global health policy decision-making. His passion for improving health literacy and disparities drove him to work with children at public schools in the Washington area, teaching a weekly course on HIV/AIDS prevention, treatment, and stigma. While completing a Pre-Medical Post-Baccalaureate program, he conducted research at the MedStar Georgetown University Hospital, focusing on healthcare disparities and the impacts of the Affordable Care Act Medicaid Expansion on access to quality surgical care. Mr. McDermott rowed on the Georgetown Varsity Crew Team and now competes in triathlons.

jimmy.mcdermott@diatribe.org
FRIDA VELCANI  
The diaTribe Foundation | Development Associate

Frida Velcani joined The diaTribe Foundation in 2019 after graduating from Vassar College Phi Beta Kappa with a degree in Science, Technology, & Society and a minor in Hispanic Studies. As an undergraduate, Ms. Velcani delved into the study of patient-centered healthcare through her multidisciplinary studies, her active involvement in public health research, and community outreach work. In her sophomore and junior years, she reported on novel technologies related to emergency response and disaster medicine as a writer for the Crisis Response Journal. Her articles highlighted ways professionals and laypeople alike could leverage technology to enhance patient engagement and improve health outcomes. While participating in the Yale Healthcare Hackathon, Ms. Velcani’s fascination with innovation and product development grew. Her team won the Yale Department of Radiology and Biomedical Imaging Prize for Medical Imaging and Process Redesign for their sleek redesign of ultrasound equipment. Ms. Velcani’s undergraduate work culminated in a thesis where she proposed technical, organizational, and personal recommendations for successful breast center microsystems and positive breast cancer screening experiences.

frida.velcani@diatribe.org

KARENA YAN  
The diaTribe Foundation | Associate

Karena Yan joined the diaTribe Foundation in 2019 after graduating from Washington University in St. Louis with a bachelor’s in Biology and Global Health and Environment. As an undergrad, she was held an executive position in WashU’s First Year Center, striving to make first year students’ transition to WashU as comfortable and seamless as possible. Ms. Yan also spent two summers at the Stanley Center of the Broad Institute of MIT and Harvard, working on project to discover biomarkers and treatments of schizophrenia. She is passionate about minority and underserved communities’ access to healthcare, serving over two hundred hours as a volunteer at Barnes Jewish Hospital, Lawrence General Hospital, and Affinia Healthcare. In her free time, she enjoys hiking, playing tennis, reading, and traveling.

karena.yan@diatribe.org